Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Agios Pharmaceuticals, Inc. (AGIO) had Return on Tangible Equity of -34.60% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$54.03M |
|
$-412.78M |
|
$6.34M |
|
$47.68M |
|
$526.16M |
|
$-472.13M |
|
$58.34M |
|
$-413.80M |
|
$-413.80M |
|
$-412.78M |
|
$-412.78M |
|
$-412.78M |
|
$-412.78M |
|
$-472.13M |
|
$-474.15M |
|
57.97M |
|
57.97M |
|
$-7.12 |
|
$-7.12 |
|
| Balance Sheet Financials | |
$942.05M |
|
$10.78M |
|
$355.17M |
|
$1.30B |
|
$82.21M |
|
-- |
|
$21.91M |
|
$104.11M |
|
$1.19B |
|
$1.19B |
|
$1.19B |
|
58.45M |
|
| Cash Flow Statement Financials | |
$-372.98M |
|
$377.18M |
|
$8.68M |
|
$76.25M |
|
$89.13M |
|
$12.88M |
|
$52.55M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
11.46 |
|
-- |
|
-- |
|
-- |
|
-- |
|
88.26% |
|
-873.87% |
|
-873.87% |
|
-877.60% |
|
-765.89% |
|
-764.01% |
|
$-377.29M |
|
-- |
|
-- |
|
-- |
|
0.04 |
|
0.19 |
|
5.11 |
|
71.46 |
|
-34.60% |
|
|
Return on Tangible Equity |
-34.60% |
-31.82% |
|
-34.60% |
|
$20.41 |
|
$-6.51 |
|
$-6.43 |
|